Last updated: February 21, 2026
What is the Drug NDC: 42747-0726?
The National Drug Code (NDC) 42747-0726 corresponds to Eptinezumab (Vyepti). This medication is an intravenously administered monoclonal antibody approved for the prevention of migraines.
Regulatory Status
- FDA Approval Date: February 2020.
- Indication: Preventive treatment for migraines in adult patients.
- Formulation: 100 mg/vial, administered every 3 months.
- Manufacturer: Lundbeck.
Market Landscape
Market Size and Demand Drivers
The migraine medication market estimated at approximately $4 billion globally in 2022 (IQVIA). The demand for preventive treatments has increased due to:
- Expanded acceptance of monoclonal antibodies.
- Elevated diagnosis rates (approx. 15% globally).
- Shift from oral preventives to biologics for better tolerance and efficacy.
Competitive Position
Eptinezumab competes primarily with:
- Erenumab (Aimovig): Subcutaneous injection.
- Fremanezumab (Ajovy): Subcutaneous injection.
- Galcanezumab (Emgality): Subcutaneous injection.
Unlike other agents, eptinezumab is administered intravenously quarterly, which influences market preferences and clinical adoption.
Key Market Participants
- Lundbeck: Brains behind eptinezumab.
- Amgen/Novartis: With Aimovig, Ajovy, and Emgality.
- Other emerging biologics and small molecules entering migraine prevention.
Pricing Dynamics
Current Pricing (as of 2023)
- Wholesale Acquisition Cost (WAC): Estimated between $4,500 to $5,100 per vial.
- Average Transaction Price: Approximately $4,200 to $4,800 per vial, owing to negotiations and insurance discounts.
- Cost per treatment cycle: Roughly $12,600 to $16,200 (since three doses per year).
Pricing Compared to Peers
| Drug |
Administration |
Approximate Cost per Dose |
Approximate Annual Cost |
| Eptinezumab |
IV every 3 months |
$4,500-$5,100 |
$13,500-$15,300 |
| Erenumab |
Subcutaneous |
$575-$630 (per dose) |
$2,300-$2,520 |
| Fremanezumab |
Subcutaneous |
$575-$635 (monthly or quarterly) |
$2,300-$2,540 |
| Galcanezumab |
Subcutaneous |
$600-$650 (monthly or quarterly) |
$2,400-$2,600 |
Reimbursement Landscape
Reimbursement is favorable, driven by efficacy data and insurance coverage. However, intravenous administration may increase administration costs and patient preference concerns.
Price Projection Considerations
Factors Affecting Future Pricing
- Market Competition: Entry of oral CGRP antagonists may suppress pricing power.
- Generic and Biosimilar Entry: Currently unavailable, but patent protections exist until at least 2030.
- Market Penetration: Increased adoption correlates with pricing stability or potential reductions due to volume growth.
- Healthcare Policies: Value-based pricing models may incentivize discounts in exchange for higher volume or improved clinical outcomes.
Short-term (2023–2025)
- Expected Pricing Range: WAC remains stable at $4,500–$5,100 per vial.
- Discounts and Rebates: Likely to account for 10–20% reductions in net prices.
Long-term (2026–2030)
- Potential for Price Reduction: Entry of biosimilars or development of oral alternatives.
- Projected Price Trend: Slight decline to $4,000–$4,500 per vial by 2030, assuming competitive pressures increase.
Strategic Implications for Stakeholders
- Pharmaceutical Companies: Price stability expected in short term; focus on expanding indications and patient access.
- Providers: Cost considerations influence formulary placement; intravenous convenience and efficacy remain key.
- Payers: Emphasize value-based arrangements, especially with high-cost biologics.
Summary
Eptinezumab (NDC: 42747-0726) maintains a high price point, with stable WAC around $4,500–$5,100 per vial, reflecting its premium biologic status for migraine prevention. Market dynamics, especially competition from subcutaneous biologics and oral agents, may exert downward pressure over the next five years. The intravenous route exceeds oral/SC alternatives on convenience but commands premium pricing to compensate for administration costs.
Key Takeaways
- The drug’s WAC remains above $4,500 per vial, with annual treatment costs nearing $15,000.
- Competitive pressures from oral CGRP agents may limit price growth and encourage volume-driven strategies.
- The patent exclusivity tilts pricing power towards the manufacturer through 2030.
- Reimbursement and insurance coverage significantly influence net prices.
- Long-term price declines are likely as biosimilar and oral options mature.
FAQ
Q1: How does the administration route impact the pricing of eptinezumab?
A1: The intravenous route incurs higher administration costs, allowing for a higher WAC compared to subcutaneous biologics, which are easier to self-administer.
Q2: What is the expected trend for eptinezumab pricing over the next five years?
A2: Short-term stability is expected; potential slight decrease to $4,000-$4,500 per vial by 2030 due to increased competition and biosimilar development.
Q3: How do insurance discounts affect the actual cost paid by payers?
A3: Rebate programs and negotiated discounts typically reduce net prices by 10–20%, lowering patient and payer costs.
Q4: What market factors could lead to price reductions?
A4: Entry of oral CGRP antagonists, biosimilar development, and expanded clinical use.
Q5: Which stakeholders primarily influence price stability or decline?
A5: Manufacturers through patent protections, healthcare providers via formulary decisions, and payers via negotiated coverage terms.
References
- IQVIA. (2022). Global Migraine Market Analysis.
- U.S. Food and Drug Administration. (2020). Vyepti (Eptinezumab) Approval Announcement.
- Berkeley Research Group. (2023). Biologic Pricing Trends.
- SSR Health. (2023). Biologic Market Price Data.
- National Comprehensive Cancer Network. (2022). Biologic Treatment Cost Summary.
